HomeBUSINESS
BUSINESS

Astellas’ Half-Year Operating Profit Down 38.8% on LLP Divestiture, Micardis Gx Erosion
(Nov.1.2017)

Astellas Pharma saw its group operating profit slide 38.8% in April-September as it offloaded its global dermatology franchise and older established assets, while facing generic competition for its heavyweight hypertension med Micardis (telmisartan) ...
(LOG IN FOR FULL STORY)

News Calendar